Recent Updates
Recently added Catalysts
WVE Negative Sentiment Score: 30/100

Wave Life Sciences Ltd. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Key Takeaway: Johnson Fistel is investigating Wave Life Sciences Ltd. for potential violations of federal securities laws in light of investor losses. This comes after a significant decline in Wave's stock following positive interim Phase 1 data from its WVE-007 clinical trial. The firm aims to determine if stakeholders can recover their losses as a result. Investors who have suffered losses are encouraged to contact Johnson Fistel for more information.

Market Sentiment Analysis

POSITIVE FACTORS

  • Recent clinical trial showed positive interim Phase 1 data for WVE-007.
  • Subjects experienced reductions in visceral fat and increased lean mass.

CONCERNS & RISKS

  • Wave Life Sciences' stock declined sharply following the clinical trial announcement.
  • An investigation is ongoing regarding potential violations of federal securities laws.

Full Press Release Details

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Wave Life Sciences Ltd. (NASDAQ: WVE) or certain of its executive officers violated federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased Wave Life Sciences securities?
If you purchased Wave Life Sciences securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the Investigation
On March 26, 2026, Wave Life Sciences announced positive interim Phase 1 data from INLIGHT, its clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA for people living with overweight or obesity.
Wave reported that, at six-month follow-up, a single 240 mg dose of WVE-007 produced placebo-adjusted reductions in visceral fat of 14.3%, total fat of 5.3%, waist circumference of 3.3%, and body weight of 0.9%, while lean mass increased 2.4%. The Company also reported that, in the 400 mg cohort, three-month data showed placebo-adjusted reductions in visceral fat of 5.0% and total fat of 0.7%, with lean mass preservation.
Following this news, Wave’s stock declined sharply, damaging investors.
In light of these disclosures, Johnson Fistel is investigating whether Wave Life Sciences complied with state and federal laws, including the federal securities laws. If you suffered losses, or are a long-term holder of Wave Life Sciences stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder class actions and derivative lawsuits. Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
James Baker, Investor Relations – or – Frank J. Johnson, Esq.

Tags

Frequently Asked Questions

What is Johnson Fistel investigating regarding Wave Life Sciences?

Johnson Fistel is investigating whether Wave Life Sciences and its executives violated federal securities laws.

What should I do if I lost money on Wave Life Sciences securities?

If you lost money after purchasing Wave Life Sciences securities, you can join the investigation.

What were the results of Wave Life's clinical trial for WVE-007?

Wave Life reported positive interim data showing significant reductions in visceral fat and body weight.

Who can assist me with my inquiry about Wave Life Sciences?

For inquiries, contact Jim Baker at jimb@johnsonfistel.com or call (619) 814-4471.

Is there any cost to participate in the investigation?

There is no cost or obligation to participate in the investigation.

Last updated: May 27, 2026